Cytokine receptor on NK cells

Cytokine receptors on Natural Killer (NK) cells are a diverse group of cell surface proteins that respond to various interleukins (e.g., IL-2, IL-12, IL-15, IL-18, IL-21) and interferons to regulate NK cell development, survival, and effector functions [1]. In modern oncology, these receptors—particularly the Interleukin-2 receptor subunit beta (CD122)—are targeted to enhance the anti-tumor activity of NK cells [2]. CD122 is a shared component of the IL-2 and IL-15 receptor complexes and is crucial for the 'signal 3' required for robust NK cell proliferation and cytotoxicity [3]. Therapeutic approaches include 'biased' cytokine agonists and multispecific NK cell engagers (such as the ANKET platform) that incorporate a cytokine receptor-binding arm to provide localized activation signals [4]. By selectively targeting these receptors on NK cells, researchers aim to avoid the systemic toxicity and regulatory T cell (Treg) activation associated with high-dose, non-selective cytokine therapies [5]. These targets are currently being evaluated in clinical trials for various hematological and solid tumors, often in combination with other immunotherapies [6]. The activation of these receptors leads to downstream signaling through the JAK-STAT pathway, primarily involving STAT5, which drives the expression of genes related to cell cycle progression and cytotoxic molecules like granzyme B and perforin [1, 3]. As part of multispecific engagers, the cytokine receptor arm helps to sustain NK cell activity within the immunosuppressive tumor microenvironment [4]. Safety monitoring for drugs targeting these receptors focuses on preventing systemic inflammatory responses and ensuring selectivity for effector cells over suppressive cell types [5]. Overall, cytokine receptors on NK cells represent a critical node in the next generation of cancer immunotherapies designed to harness the innate immune system [2, 6].

Other names

NK cell cytokine receptorCD122Interleukin-2 receptor subunit betaIL-15 receptorIL-21 receptorIL-12 receptorIL-18 receptorCommon gamma chain (CD132)

Agonism of cytokine signaling pathways, particularly the IL-2/IL-15 pathway via the CD122 (IL-2Rβ) subunit, to stimulate Natural Killer (NK) cell proliferation, survival, and effector functions. This is often achieved through 'biased' agonists that avoid CD25 (IL-2Rα) to prevent regulatory T cell activation, or via multispecific engagers that tether the cytokine signal directly to the NK cell-target cell synapse.